ArticleEuropean addiction research2023
Anabolic Androgenic Steroid Use Patterns and Steroid Use Disorders in a Sample of Male Gym Visitors.
Article in European addiction research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 27 citations in OpenAlex.
- Anabolic Androgenic Steroids: Emerging Use Disorder, Mechanisms of Action, and Clinical Considerations for Pharmacotherapy.Focus (American Psychiatric Publishing) · 2026Article
- Anabolic-androgenic steroid use disorder: case for recognition as a substance use disorder with specific diagnostic criteria.The British journal of psychiatry : the journal of mental science · 2026Review
- Understanding Age-Based Differences in Psychosocial Harms, Physical Harms, and Access Difficulties Among an International Sample of Men Who Use Anabolic-Androgenic Steroids.American journal of lifestyle medicine · 2025Article
- Article
- Adulteration of Sports Supplements with Anabolic Steroids-From Innocent Athlete to Vicious Cheater.Nutrients · 2025Review
- Prolonged post-androgen abuse hypogonadism: potential mechanisms and a proposed standardized diagnosis.Frontiers in endocrinology · 2025Review
- Harm reduction techniques among cisgender gay, bisexual, and queer men using anabolic androgenic steroids: a qualitative study.Harm reduction journal · 2024Article
- Exploring Anabolic Androgenic Steroid Use Among Cisgender Gay, Bisexual, and Queer Men.JAMA network open · 2024Article
- Supraphysiological testosterone levels from anabolic steroid use and reduced sensitivity to negative facial expressions in men.Psychopharmacology · 2024Article
- Exploring the prevalence of anabolic steroid use among men and women resistance training practitioners after the COVID-19 pandemic.BMC public health · 2024Article
- The Uses of Anabolic Androgenic Steroids Among Athletes; Its Positive and Negative Aspects- A Literature Review.Journal of multidisciplinary healthcare · 2023Review
Corrections and comments
- Erratum issuedErratum.2023
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe use of anabolic androgenic steroids (AAS) and other image- and performance-enhancing drugs is a growing public health concern. AAS use is associated with various physical and mental harms, including cardiovascular risks, cognitive deficiencies, and dependence. The aim of this study was to determine whether patterns of AAS use and other variables are associated with the presence of an AAS use disorder (AASUD).
methodsAn online survey was completed by 103 male AAS consumers visiting gyms. The association of different patterns of AAS consumption (cycling vs. continuous forms of AAS use), psychoactive substance use, mental health disorders, and sociodemographic variables with moderate-severe AASUD (fifth edition of the Diagnostic and Statistical Manual of Mental Disorders ≥4 criteria) was investigated. The associations between duration of AAS use and the AAS dose with moderate-severe AASUD were investigated using logistic regression analysis with moderate-severe AASUD as the dependent variable.
resultsModerate-severe AASUD was present in 25 (24.3%) of the participants. AAS consumers meeting criteria for moderate-severe AASUD, compared to those that did not, in the last 12 months reported a longer duration of AAS use (in weeks), a higher average AAS dose (mg/week), and a greater number of AAS side effects. Duration of AAS use and the AAS dose were the only independent predictors, with an increase of 3.4% in the probability of moderate-severe AASUD with every week increase of the duration of AAS use in the last year (p < 0.05) and an increase in moderate-severe AASUD of 0.1% with every 10 mg increase in the average AAS dose per week (p < 0.05), respectively.
conclusionOur findings show that moderate-severe AASUD is relatively frequent among male AAS consumers and is positively associated with the duration and average dose of AAS use in the last 12 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.